http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022215763-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2694fd4c63bfaa7635c0c1ff05d8af5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2021-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e62f53e37e37b0681d8bc6ccd2482c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd4defec7a119bd54fd51a70e345c68d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434bc6196fa8b6da09d9c44cf9a98743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ca10a4c508f18831eb63712f6ff688 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b315374014280d43acbd7f074d99edb |
| publicationDate | 2022-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022215763-A1 |
| titleOfInvention | Chimeric antigen receptor targeting oncolytic virus-derived protein, immunocyte expressing same, and uses of both |
| abstract | The present invention relates to a chimeric antigen receptor targeting an oncolytic virus-derived protein, an immunocyte expressing same and uses of both. Particularly, the present invention relates to: a chimeric antigen receptor targeting protein A56 expressed on cell surfaces of cancer cells infected with vaccinia virus; an immunocyte expressing same; and uses of both. An immunocyte expressing a chimeric antigen receptor, of the present invention, effectively targets protein A56, specifically expressed on cell surfaces of cancer cells, so as to enable targeted therapy of cancer cells that remain even when infected with an oncolytic virus, and thus effective anti-cancer therapy can be provided. An immunocyte expressing a chimeric antigen receptor, of the present invention, specifically activated by protein A56, has an increased proliferation capability, and exhibits excellent cytotoxic effects so that effective anti-cancer therapy for cancer cells expressing protein A56 can be provided. Preferably, the present invention is co-administered with an oncolytic virus, and drugs (for example hydroxyurea, chemotherapeutic agents for lymphodepleting conditioning (for example cyclophosphamide, fludarabine, and the like), or immunotherapeutic agents) capable of increasing oncolytic effects of the oncolytic virus can be additionally co-administered. |
| priorityDate | 2021-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 562.